Esperion Presents Two CLEAR Outcomes Study Late-Breakers at

– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of...

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Alexis Callahan ,Stephen Nicholls ,Tiffany Aldrich ,Sheldon Koenig ,Kausikk Ray ,Twitter ,Phd Victorian Heart Institute ,Exchange Commission ,Fmedsci Imperial College London ,Monash University ,European Society Of Cardiology ,Late Breaking Science Session ,European Society ,Victorian Heart Institute ,New Onset Diabetes ,Glycaemic Status ,Bempedoic Acid ,Prespecified Analyses ,Imperial College London ,Prescribing Information ,Contact Information ,Nasdaq Espr ,Esperion Therapeutics ,Nc ,